• Gene fusion; HGNC; HGNC:3819; FOXO1 + HGNC; HGNC:8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=8275086; PubMed=23578105; PubMed=25806826).
  

PubMed=8275086; DOI=10.1038/ng1193-230
Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. 3rd, Emanuel B.S., Rovera G., Barr F.G.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Nat. Genet. 5:230-235(1993)

PubMed=7536457; DOI=10.1002/gcc.2870120305
Biegel J.A., Nycum L.M., Valentine V.A., Barr F.G., Shapiro D.N.
Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization.
Genes Chromosomes Cancer 12:186-192(1995)

PubMed=9823299
Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Cancer Res. 58:5009-5013(1998)

PubMed=19235922; DOI=10.1002/gcc.20655
Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C., Koster J., Summersgill B.M., Messahel B., Versteeg R., Pritchard-Jones K., Kool M., Shipley J.M.
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Genes Chromosomes Cancer 48:455-467(2009)

PubMed=23578105; DOI=10.1111/cas.12173; PMCID=PMC7657110
Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R., Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y., Ogawa S.
Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Cancer Sci. 104:856-864(2013)

PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)

PubMed=25806826; DOI=10.1371/journal.pone.0121474; PMCID=PMC4373809
Schmitt-Ney M., Camussi G.
The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-beta pathway.
PLoS ONE 10:E0121474-E0121474(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=36768928; DOI=10.3390/ijms24032601; PMCID=PMC9917031
Timpanaro A., Piccand C., Uldry A.-C., Bode P.-K., Dzhumashev D., Sala R., Heller M., Rossler J., Bernasconi M.
Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma.
Int. J. Mol. Sci. 24:2601.1-2601.28(2023)